Compare Ascendis Pharma A/S (ASND) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Norfolk Southern Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Norfolk Southern Corporation trades at $327.47 (market cap $73.55B). The key difference: Norfolk Southern Corporation is far larger — about 4.1× Ascendis Pharma A/S's market cap, and Norfolk Southern Corporation pays a 1.65% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NSC | |
|---|---|---|
Market Cap | $17.74B | $73.55B |
Sector | Health | Technology |
52-Week High | $277.18 | $327.47 |
52-Week Low | $163.32 | $259.49 |
Enterprise Value | $18.11B | $89.31B |
Dividend Yield | — | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Norfolk Southern (NSC) trades at $327.47, up 1.14% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.65 exceeding expectations of $2.49. Valuation metrics include a P/E of 27.59 and ROE of 17.6%, while analyst consensus targets $342.67. Recent developments include the pending merger with Union Pacific and upcoming Q2 2026 earnings on July 23, 2026.
NSC presents a favorable investment case with strong profitability and merger potential, though regulatory scrutiny and rich valuations pose risks. The stock's proximity to 52-week highs suggests limited near-term upside, but long-term growth prospects remain solid if merger approvals proceed smoothly and operational efficiency improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
